title: Pharmacokinetics of rocuronium during the three stages of liver transplantation.
abstract: BACKGROUND
  Little is known about the influence of liver transplantation on the pharmacokinetics of most anesthetic drugs. The authors determined the pharmacokinetics of rocuronium during liver transplantation and examined whether variability in pharmacokinetics could explain variability in recovery of neuromuscular function.
  
  
  METHODS
  Twenty patients undergoing liver transplantation were given rocuronium, 600 microg/kg, after induction of anesthesia and again after perfusion of the transplanted liver. Plasma was sampled to determine rocuronium concentrations. Pharmacokinetic models were fit to rocuronium concentrations versus time data using a mixed-effects population approach. Various models permitted changes in clearance (Cl) or central compartment volume to account for changes in hepatic function and circulatory status during the paleohepatic, anhepatic, and neohepatic periods. Time to initial recovery of four twitches of the orbicularis oculi was determined.
  
  
  RESULTS
  During the paleohepatic and anhepatic periods, the typical value of Cl was 2.47 ml x kg(-1) x min(-1) and was not influenced by the magnitude of preexisting liver disease (as evidenced by prothrombin time, bilirubin, serum albumin, alanine transaminase [ALT], and aspartate transaminase [AST]). During the neohepatic period, the typical value of Cl varied as a function of the duration of warm ischemia of the hepatic allograft and was 2.72 ml x kg(-1) x min(-1) for a patient with an average 60-min period of warm ischemia; time to neuromuscular recovery varied as a function of Cl.
  
  
  CONCLUSIONS
  Despite prolonged hypothermic ischemia, the newly transplanted liver eliminates rocuronium as well as the diseased native liver (and comparably with historical control values). However, some patients had decreased rocuronium Cl during the neohepatic period, apparently a result of prolonged graft warm ischemia. The authors' finding of preservation of hepatic drug elimination in the hepatic allograft is consistent with limited data for other drugs evaluated during anesthesia.
authors.affiliation: Department of Anesthesia, University of California, San Francisco 94143-0648, USA. fisher@zachary.ucsf.edu
authors.forename: D M
authors.initials: DM
authors.lastname: Fisher
authors.forename: M A
authors.initials: MA
authors.lastname: Ramsay
authors.forename: H A
authors.initials: HA
authors.lastname: Hein
authors.forename: R J
authors.initials: RJ
authors.lastname: Marcel
authors.forename: M
authors.initials: M
authors.lastname: Sharma
authors.forename: K J
authors.initials: KJ
authors.lastname: Ramsay
authors.forename: R D
authors.initials: RD
authors.lastname: Miller
mesh_terms: D000328:Adult; D000368:Aged; D000732:Androstanols / Q000097:blood / Q000493:pharmacokinetics*; D000768:Anesthesia, General; D005260:Female; D006801:Humans; D008099:Liver / Q000378:metabolism / Q000502:physiology; D008107:Liver Diseases / Q000378:metabolism / Q000601:surgery; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D003473:Neuromuscular Nondepolarizing Agents / Q000097:blood / Q000493:pharmacokinetics*; D010477:Perfusion; D000077123:Rocuronium; D013997:Time Factors
chemical_list: D000732:Androstanols; D003473:Neuromuscular Nondepolarizing Agents; D000077123:Rocuronium